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Science works on the frontier between knowledge and ignorance. We’re not
afraid to admit what we don’t know. There’s no shame in that. The only
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Abstract
Introduction The shortage of organs for patients is an issue that needs addressing.
Xenotransplantation using pig cells or organs is the most favored option. However, pigs
contain porcine endogenous retroviruses (PERV) in their genome which infect human
cells. Like all retroviruses PERVs have immunosuppressive properties and may induce
tumors. The mechanism of immunosuppression is unclear, but in the transmembrane
envelope protein p15E a so-called immunosupppressive (isu) domain was identified. To
prevent PERV transmission, a vaccine based on neutralizing antibodies may be useful.
Previous results showed that immunization with TM proteins with mutations in the isu
domain induced higher titers of antibodies compared with the wild-type.
Methods and results To develop an improved vaccine against PERVs, mutations were
introduced in the isu domain after sub-cloning of env of PERV-A(42). Since the molecular
clone PERV-A(42) was found not replication-competent, the mutants could not be tested
in vivo . Although mutations in the env gene could not be detected, Western blot and
immunofluorescence analysis, as well es transmission electron microscopy demonstrated
the release of so-called Gag particles. To circumvent these shortcomings a PERV-A/B
hybrid was generated, introducing the env of PERV-A(42) into a non-functional PERV-
B(33). In addition, vectors were generated expressing the wild-type and mutated Env
proteins. To analyze the influence of PERV on human immune cells, a virus preparation
of recombinant PERV-A/C was added to human PBMCs and the release of IL-10 was
analyzed. A low production of IL-10 was observed. Although the virus preparation was
minimally contaminated with endotoxin, also able to induce IL-10, an inhibitor of the
receptor of endotoxin, TAK-242, did not inhibit the whole activity.
Discussion The produced recombinant wild-type and mutant p15E will allow testing
for the activity to induce IL-10 and other cytokines and will be used for immunization.
Since PERV-A(42) was not replication-competent, other strategies have to be followed to
obtain viruses with and without mutations.
1
1. Introduction
1.1. Background and clinical relevance
Organ transplantation is an important issue today. In 2013, 11233 people in Germany
alone were registered on the Eurotransplant waiting list. At the same time, only 4511
organs were available through German donors [1]. It is therefore of importance to find a
way to close this gap. Many promising ideas to develop novel techniques to overcome this
problem are currently under investigation. One approach is to grow new organs from stem
cells. This field of research however remains highly controversial and so far only offers
limited success. It is for those ethical dilemmas that research groups around the world
are trying to produce induced pluripotent stem cells which can then be used to generate
organs. The nature of those therapies, as promising as they may sound, however includes
serious set backs. Heart tissue generated from stem cells usually does not conduct electric
current and is therefore non-functional. In other cases, even harmful effects can arise from
these approaches. Cases are reported that generated heart cells will perform contractile
movement counteracting the remaining hearts tissue [2].
Another method is to utilize organs from donor species other than human, to perfrom
Xenotransplantations (xenos, from the Greek: foreign).
Here, cells or tissues are harvested from species other than the recipient species and
transplanted into the host to replace the damaged tissue. Various problems arise from this
technique. Like in human-human transplants immunological compatibility is an issue. As
all cells present self-protein via major histocompatibility complex I (MHC I) to natural
killer cells (NK cells) as well as to cytotoxic T-cells, cells from a different donor than
oneself present a different set of proteins via a slightly different type of MHC I. In the
case of immune rejection, NK cells as well as cytotoxic T-cells trigger rejection of the
donor organ. Other mechanisms of rejection include the recognition of foreign antigen.
2
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In pigs galactose-alpha-1,3-galactose (αGal) is such an antigen [3]. As it is not produced
by primates, antigen presenting cells can activate B-cells, which will produce antibodies,
specifically targeting αGal leading to the activation of the complement system and in the
destruction of the donor tissue.
1.2. Retroviridae
Retroviruses are (+)RNA viruses that carry a reverse transcriptase (an RNA dependent
DNA polymerase), which allows the virus to rewrite its genome into a coding strand
of DNA, which is in turn integrated via an integrase into the hosts genome (Figure
1.1)[4]. Retrovidae are comprised of two subfamilies: orthoretroviridae and spuma retro-
viridae. Seven genera can be found in orthoretroviridae: Alpharetroviruses, Betaretro-
viruses, Deltaretroviruses, Gammmaretroviruses, Epsilonretroviruses and Lentiviruses.
Spumaviridae on the other hand is soley comprised of the Foamyvirus-genus. Whether or
not a virus is considered a complex retrovirus depends on if it carries accessory proteins,
which are encoded by alternatively spliced RNA transcripts [5]. When budded from the
host cell, the virus particle is still immature and undergoes a maturation process via
protease activity (Figure 1.4). The virion itself, like in all retroviruses measures about
100-150 nm in diameter. The mushroom like structures protruding from the particle are
comprised of the surface unit (SU), which is attached to the lipid bilayer of the viral
envelope via the transmembrane (TM) domain. The viral core , which contains the viral
genome as well as reverse transcriptases, integrases, and nucleocapsid proteins.
When the germline of an organism becomes infected with a retrovirus, all resulting
cell from mitosis now contain endogenous retroviruses (ERVs). Porcine endogenous retro-
viruses can be found in all pigs and can form infectious particles[7, 8].
1.3. Genome organization of porcine endogenous
retroviruses
The approximately 8 kb genome consists of two (+)RNA flanked by long terminal repeats
(LTRs) which contain U5 (unique), R (redundant) and U3 elements (Figure 1.3). These
elements are the site of promoters and enhancers, as well as they mark the site of Poly(A)
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Figure 1.1.: An illustration of different events in the life cycle of a retrovirus. a) Entry:
Viral particle needs a specific receptor on cell surface to bind leads to fusion
of membranes (omitted here). The viral core uncoates and reverse transcrip-
tase generates DNA from genomic +RNA. After transit through cytoplasm
and nuclear entry, viral DNA integrates into the host’s genome resulting in
a provirus. b) Viral exit: RNA polymerase II transcribes provirus and viral
RNA is processed and exported out of the nucleus. Viral proteins are trans-
lated from RNA template and Gag assembly and RNA packaging take place.
The virus then buds through the cellular membrane and matures when it has
already exited the cell [6].
addition. For reverse transcription to occur, a primer binding site (PBS) is located at
the U5 element which binds to an intracellular tRNAGly to initiate reverse transcription
[10]. Through splicing of the genome two variants arise. One spliced variant comprises
the full length sequence which code for Gag and Pol. The other variant codes for Env
and is about 3 kb in size. Viral protease, matrix, capsid, and nucleocapsid proteins are
encodde by the gag gene, while pol codes for reverse transcriptase and integrase (compare
Figures 1.3 & 1.4).
1.4. Safety
Other dangers might arise from the donor’s tissue itself. Pigs, as well as a humans, and
all other mammals, have retroviral DNA encoded within their own genome. These retro-
viruses are therefore termed; endogenous retroviruses.PERVs unlike human endogenous
retroviruses (HERVs) are able to form particles which are still exiting the cells in which
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Figure 1.2.: Dendrogram of virus classes of endogenous retroviruses. Unrooted Pool neigh-
bor joining denrogram of seven retroviral genera. Represented are, alpha-,
beta-, gamma-, delta-, epsilon-, lenti- and spuma-like retroviruses. Endoge-
nous retroviral classes which are more loosely defined are indicated on the
periphery. Host species are described by symbols adjacent to the taxonomic
unit. New sequences are named according to their position in their host chro-
mosome (e.g. hg15 and 16: Human genome; gg01: Chicken genome and pt01:
chimpanzee genome). Both pt01 sequnces were only observed in chimpanzees
[9].
Figure 1.3.: Proviral sequences of 293-PERV-A(42), PK15-PERV-A(58) and PK15-
PERV-B(213) are 8,849, 8,918, and 8,763 bp in length, respectively.A.11[11]
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Figure 1.4.: Illustration of the immature (left) and mature (right) virion of a retrovirus.[12]
they are produced and therefore reach the circulation of the organism in which they are
present. Despite an enormous increase in knowledge concerning PERVs, the overall safety
analysis of pigs which may be used for xenotransplantation is limited. The infectious risks
caused by the presence of numerous PERVs in the pig genome and the possible impact
of PERVs on the health of the recipient is badly studied due to the lack of an appro-
priate animal model.All pigs harbour PERVs as an integral part of their genome [13]
and PERVs are known to infect human cells in vitro [7, 8]. Although no transmission
of PERV has so far been observed in non-clinical and clinical xenotransplantation [14],
strategies should be developed preventing virus transmission. However, there is evidence
for adaptation of PERVs to human cells [15, 16] and for immunosuppressive properties
[17, 18]. Because of the transspecies transmission of the human immunodeficiency viruses
(HIVs) which induces fatal immunodeficiencies in the infected individuals, the risk that
PERVs induce immunodeficiencies and/or tumours in the transplant recipient cannot be
excluded. Furthermore, closely related retroviruses such as the murine leukaemia virus
(MuLV), feline leukaemia virus (FeLV) and the Koala retrovirus (KoRV) induce tumours
and immunodeficiencies in the infected hosts [19]. Moreover, α1,3-galactosyltransferase
(α1,3GT) gene knockout pigs [20–22] may present a new risk for xenotransplantation, be-
cause PERV released from these animals lack α1,3-galactose residues in the viral envelope
and therefore could escape the complement cascade [23].
Another risk relates to recombinant PERVs. Recombination between human-tropic PERV-
A and ecotropic PERV-C has been observed in pigs under natural conditions. Co-
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cultivation of PERV-A and PERV-C in pigs has shown to yield recombinant human-tropic
replication competent PERV-A/C [24, 25], some of which integrate into the genome of
certain pig cells, but not the germ line, behaving like exogenous viruses [26]. PERV-A/Cs
infect human cells and adapt to form high-titer viruses [16, 27–29]. Over millions of
years host organisms have developed protective mechanisms to avoid retroviral infection
and limit expression of integrated viruses. These are mediated by intracellular proteins
termed ’restriction factors’, which are components of the innate immune system that act
at different stages in the retroviral replication cycle. Some families and factors, such as
APOBEC, Fv1, tripartite motif (TRIM)5α, TRIM28, ZAP and tetherin provide a barrier
against γretroviral and lentiviral infections, including HIV[30–32].
To detect PERVs, direct and indirect detection methods were developed by this lab
[14]. Direct methods include: detection of proviral DNA by PCR, quantitative real time
PCR, or Southern blot; detection of viral RNA or mRNA expression by RT-PCR or
real time RT-PCR; detection of spliced mRNA as criteria for env expression, detection of
protein expression by immunofluorescence. Indirect methods empoloyed are either ELISA
or Western blot analyses.
1.5. Aim of study
The final aim of the project is to induce an improved preventive vaccine against infection
by PERVs as one possible strategy to prevent virus transmission. PERVs are integrated
in the genome of all pigs, they are released from normal pig cells, and infect human cells.
Like most retroviruses, PERVs may possibly induce immunodeficiencies and promote the
establishment of tumors in the infected host.
How retroviruses induce immunosuppression is still unclear. However, it was shown that
viral preparations of different retroviruses, their recombinant TM proteins and synthetic
peptides corresponding to the so-called immunosuppressive domain of the retroviral TM
proteins were able to modulate cytokine release and gene expression in normal peripheral
blood mononuclear cells [33–36]. Il-10, IL-6 and IL-8 were upregulated, IL-2 and some
genes involved in innate immune responses were down regulated, suggesting that the
immunosuppressive domain of the transmembrane protein may be involved.
Neutralizing antibodies were induced by immunisation with the PERV transmembrane
7
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and surface envelope protein [37, 38]. It was shown that mutations in the immunosuppres-
sive domain of the TM protein of different retroviruses including HIV-1 abolishes their
immunosuppressive properties in vivo and immunization with the mutated TM protein
induces higher antibody responses in the immunised animals when compared with the
wild-type TM protein [33–36].
Therefore, immunization with mutated p15E of PERV may induce higher titers of neu-
tralizing antibodies than with the wild type. To investigate this, a replication-competent
clone should be characterized in its wild-type form and mutated to observe and measure its
effect on cytokine release when it interacts with human peripheral blood mononucleated
cells (PBMC). Furthermore, mutated and non-mutated versions of env in an expression
vector (pTarget)for protein expression should be established. Additional efforts were un-
dertaken to produce PERV-A/B hybrid clones, which include the PERV-A(42) Env cloned
into an Env-deficient PERV-B clone, to restore the virus’ infectivity.
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2. Methods
2.1. Virus production and purification
PERV producing HEK293T cells were grown using standard cell culture medium (A.8)
and grown to confluency. Supernatant was harvested and through a series of centrifuga-
tion steps (using Heraeus Centrifuge, Appendix A.6) separated from remaining cells, as
well as cellular debris. The steps include centrifugation at 1200 rpm for 10 min followed
by another 10 min interval at 4000 rpm. To remove further debris from the sample, a cell
strainer ( Appendix A.6) is used. The supernatant then undergoes ultracentrifugation
(A.6) at 34000 rpm for 130h to pellet the produced virus using rotor SW41. This pellet
is then re-suspended in a scraping motion with PBS and used for purification using a
20% sucrose solution and a lighter phase material (here PBS). The resuspended pellet
ins injected into the phase between the two layers and centrifuged at 38000rpm in the
ultracentrifuge (Rotor: SW50.1) to obtain the virus pellet in the sucrose solution. After
careful removal of supernatant, the pellet contained in the bottom phase is re-suspended
in PBS to obtain the desired concentration from measured from original amount of su-
pernatant harvested and processed (Equation 2.1).
Example:
100mLSupernatant ⇒ resupsended in 100µL = 1000× (2.1)
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2.2. Characterization of the PERV-A(42) clone
A clone, which was provided by Ralf Tönjes from the Paul Ehrlich Institute, Langen, was
transformed into chemically competent cells (JM109, A.3) using the standard protocol
provided by the vendor (Zymo Research, A.3). An isolated colony was picked and grown
overnight in LB+AMP medium (A.8) at 37 oC in a shaking incubator (A.6) at 180 rpm.
To confirm the identity of the clone, a restriction digest using, PstI and HindIII. Digest
was set up as described in table 2.1.
Table 2.1.: Set up for restriction digest to characterize PERV-A(42) clone. Appendix A.4
for more information.
Component Amount (in µL)
10× Fast Digest Buffer 1
Restriction enzyme 1
DNA sample (total of ≈ 200 ng) 2
H2O (fill up to final vol. here 10 µL) 6
Total 10
The resulting fragments have been confirmed on a 1% agarose gel as illustrated in
figure 3.1.
2.3. Polymerase chain reaction
Polymerase chain reaction (PCR) performed using several different DNA dependent DNA
polymerases. In general, a Taq polymerase (A.4) was used for short fragments and colony
PCR as well as for TA- cloning, due to the template independent 3’ T overhang it produces.
Taq polymerase has a much higher error rate as compared to Phusion polymerases (Hot
start flex A.4) which I used to perform site-directed mutagensis as well as for several
cloning applications which included the amplification of long terminal repeats of viruses.
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Table 2.2.: a) Setup for GoTaq-Master Mix and b)Phusion Hot Start Flex
(a) Setup of 50 µL Reaction
Component Amount
(µL)
GoTaq Green Master Mix 25
Forward Primer (10 µM) 1
Reverse Primer (10 µM) 1
DNA Template (≈100ng) x
Nuclease Free H2O x
Total 50
(b) Setup of 50 µL Reaction
Component Amount
(µL)
5× Phusion HF or GC Buffer 10
10 mM dNTPs 1
Forward Primer (10 µM) 2.5
Reverse Primer (10 µM) 2.5
DNA Template (<250 ng) x
Nuclease Free H2O x
Phusion Hot Star Polymerase 0.5
Total 50
Table 2.3.: Thermocycler settings for PCR amplification (30-40 cycles)
GoTaq Green Master Mix Phusion Hot Start Flex
Phase Temperature (in oC) Time (seconds)
Denaturation 95 120 300
Annealing Tm - 5 30 15
Extension 72-74 ( 1 kb
min
) ( 2 kb
min
)
Final extension 72-74 300
Storage 4 ∞
2.4. Cloning
Previously obtained PERV-A clone (accession №AJ133817) was transformed into com-
petent cells (JM109, A.3) using the standard protocol provided by the vendor (Zymo
Research, A.3). An isolated colony was picked and grown overnight in LB+AMP medium
(A.8) at 37 oC in a shaking incubator (A.6) at 180 rpm. The plasmids were isolated and
the Env region containing p15E, was amplified using GoTaq® Green Master Mix in PCR
reaction (table 2.4 for primers). Exemplary thermocycler settings can be found in table
2.3.
Table 2.4.: Primers for env amplification
Name Sequence Tm
Forward env - Primer 5’-TTTGTTCTCTAGGCTCAAGGCG-3’ 66.5 oC
Reverse env - Primer 5’-TTCTAATCTTAGAACTGGGAAGG-3’ 59.3 oC
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After PCR, fragment length was determined using 1% agarose gel, as seen in figure 3.8
The remaining PCR product was purified using Invisorb™ DNA CleanUp (A.5, concen-
tration: ≈350 ng
µL
) and was cloned into the pGEM®-T Vector using the protocol provided
by the vendor (A.10).
The resulting construct was then transformed into JM109 cells using the previously
described protocol. Plasmids were isolated from bacterial culture (using Invisorb®: Ap-
pendix A.5) Spin Plasmid Mini Two) after an 8 hour growth period in 4 mL of bacterial
medium (A.8) and confirmed via restriction digest with NotI and consecutive sequencing.
The isolated plasmid construct served as the basis for site-directed mutagenesis (2.6).
2.5. Transfection
Target cells (293T cells, A.3) were transfected with wild type (WT) PERV-A(42) to
elucidate its ability to form particles as well as various mutated forms for virion harvest
and purification. Previously, 293T cells were seeded onto 6 well cell culture dish and
grown to ≈ 80 % confluency at 37 oC in CO2 incubator. 250 µL of cell culture medium
without antibiotics (A.8) and 2.5 µg of DNA are mixed and 7.5 µL of transfection reagent
(A.8) are added and mixed via short vortexing. The solution was incubated at room
temperature (RT) for 20 min. After incubation the solution is added drop-wise to each
well and incubated at 37 oC in a CO2incubator for 24-48 hours. Virus particles can now
be harvested and purified by harvesting supernatant and cell lysate can be analysed for
transfected material as well as viral proteins. For further details and variations of the
protocol the vendors manual can be consulted (A.8).
2.6. Site-directed mutagenesis
Site-directed mutagenesis was performed by ”back to back” PCR of the PERV-A(42)
clone-DNA. Here, two primers anneal at the site of the desired mutations on the coding
as well as template strand of the template DNA, at in consecutive order (2.2). The
primers are therefore attached to the template in a back to back fashion and synthesize
the complete template strand including the desired mutations (Figure 2.1). The template
was digested via DpnI digest. This a linear fragment of DNA, is ligated (2.15) to form a
circular piece of plasmid DNA and transformed into competent cells (2.2).
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Figure 2.1.: Illustration of mutations to be induced from WT PERV-A(42) infectious clone
(A.11). Mutations are introduced into construct shown in figure 3.8 by site-
directed mutagenesis (2.6).
Figure 2.2.: Diagram of the work-flow of site-directed mutagenesis. 1) original clone
(PERV-A(42)) with phosphorylated primers (mutations indicated with red
crosses) annealed. 2) linear amplicon containing mutations. 3) Clone after
ligation reaction with T4-Ligase. Ligated Clone contains desired mutations.
2.7. Generation of clones for protein expression
Protein expression clones were created by producing amplicons from clones created via
site-directed mutagensis as well as wild type PERV-A(42) using primers (trunc-env-
Forward, trunc-env-Forward-kozak, and trunc-env-reverse-close, A.9)(Figure 3.14). PCR
reaction set up and thermocycler settings were adjusted according to GoTaq Green Mas-
ter mix protocol (Tables 2.2 and 2.3). Primers were designed to truncate Env before its
transmembrane domain, as illustrated in figure 2.3.
Amplicons were isolated from a 1 % agarose gel using Invisorb® Spin DNA Extraction
Kit (A.5) and quantified. Those fragments were used for cloning using the pTarget™ -
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Figure 2.3.: Prediction of location of transmembrane domain in Env. Black vertical
line represents cut-off at 583 aa as used in generation of Env-expression-
clones.Diagram was created using Phobius from the bioinformatics centre
Stockholm.
Vector System as described in section 2.4. The resulting clones were transformed according
to protocol in section 2.4 and plasmid DNA was isolated using Invisorb® Spin Plasmid
Mini Two (A.5). KpnI digests were performed according to protocol described in table
2.1. The resulting fragments can be seen in figure 3.17. After verification of directionality
of inserts, sequencing as described in section 2.8 was carried out to confirm the presence
of the mutations as well as the partly modified transcription start site through addition
of Kozak sequence (Figure 3.18).
2.8. Sequencing
All sequencing reactions were performed at the Robert Koch Institute is an advanced
chain-terminator method, which employs ABI BidDye 3.1v cycle sequencing. Sequencing
PCR was performed using thermocycler settings in table 2.5
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Table 2.5.: Sequencing PCR setup
(a) Reaction setup
Component Amount (µL)
DNA template 200 ng
Primer (10 µM 0.5
BigDye-Mix 3.1 1
5× ABI-buffer 1.5











Cell culture cells are collected at ≈ 108cells
mL lysis buffer
and washed three times with cold PBS.
Supernatant is removed and cells are resuspended in 2 × NP40 lysis buffer (A.2) +
cOmplete (A.8) and incubated for 30 min on ice, while vortexing every 10 min. Cellular
debris is pelleted at 13,000 rpm for 10 min and clear supernatant is collected in new
centrifuge tube and can now be stored at - 80 oC for use in SDS-PAGE.
2.10. SDS PAGE
A 12 % sodium dodecyl sulfate (SDS) polyacrylamide separation-gel with a 4 % stacking-
gel was used to detect proteins within samples. The composition of the gel and its buffers
can be seen in table 2.6.
Table 2.6.: SDS-PAGE according to Jagow and Schägger [39].
Stock solution for SDS-PAGE
Buffer Tris (M) Tricine (M) pH SDS (%)
Annode Buffer 0.2 ∅ 8.9a ∅
Cathode Buffer 0.1 0.1 8.25b 0.1
Gel Buffer 3.0 ∅ 8.45a 0.3
a Adjusted with HCL
b No correction of the pH, which is around 8.25.
10 µL of samples were with 10 µL Novex® Tris-Glycine SDS Sample Buffer (A.8 (2×)
with 5 % beta-mercaptoethanol to reduce intra or intermolecular disulfide bonds. The
resulting 1× solution was denatured at 95 oC for 10 min and then loaded onto the previ-
ously prepared gel for analysis. Voltage settings for stacking gel were 80 V for ≈20 min
and 110 V for separation gel for ≈70 min. Times are approximated due to the varia-
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tion in gel-fraction-size. The resulting gel can now be used for Western blot analysis or
Coomassie blue staning.
2.11. Western Blot analysis
The transfer chamber is prepared using one layer of extra thick blotting paper, a matching
piece of Optitran BA-S 83 (GE) membrane on which the gel is placed. The gel is covered
with one piece of extra thick blotting paper. All pieces of this assembly are previously
soaked in transfer buffer (A.2). To improve the transfer, potential air bubbles are pushed
out by a rolling and pushing after the the transfer is assembled. To cover the full spectrum
of proteins of interest, a 1 hour transfer at 20 V is sufficient.
After the transfer, the recovered membrane is blocked over night at 4 oC or for 1h at
RT in 6 % milk in PBST (PBS supplemented with 0.1 % Tween) can be probed with
several antibodies. The Antibodies used in my experiments were derived from earlier
PERV immunization studies conducted with goats. It was determined that these serum-
Antibodies are to be used at a 1:500 dilution in 6 % milk in PBST for 1h at RT. The
process was followed by three consecutive 5 min washing steps in PBST on a shaking
platform. The secondary antibody (A.1) was added in a 1:10000 dilution in 6 % milk
in PBST for 1h. The membrane was developed using ECL Western Blotting Detection
Reagents Kit (A.5) according to the protocol provided. Visualization was achieved using
CHEMOCAM Imager 3.2 (A.6)
2.12. Coomassie blue stain
SDS-PAGE gel is washed with lukewarm ddH2O three consecutive times for 5 minutes
each on a shaking platform. Coomassie blue R250 (A.2) is added and covered with a
lid on a rocking platform for ≈15 minutes. After staining, Coomassie blue solution is
removed and the gel is destained using 50 % destaining solution (A.2) and 50 % ddH2O
overnight. Visualization was achieved using CHEMOCAM Imager 3.2 (A.6) including a




Previously cells were seeded out to grow to ≈ 50 % confluency and were transfected
according to section 2.5. Newly transfected cells were fixed with 2 % paraformaldehyde
for 20 min at 37 oC. Cells are washed twice with PBS and and placed on ultra adhesive
microscope slide and dried at 37 oC until liquid has evaporated. Permiabilization was
performed with a 0.2 % Saponin solution for 30 min and blocked with blocking buffer for
2 hours at RT (A.2). Primary antibodies (A.1) used are diluted in antibody-dilution buffer
(A.2) and applied at various concentrations directly on top of the sample for 1 hour. Cells
are washed three times using IF- wash buffer (A.2) and incubated with secondary antibody
(A.1) for 45 min. The secondary antibody is conjugated with fluorophores resulting in
the signal observed (3.5). As those fluorophores are light-degradable, incubation has to
take place in the dark. Finally, cells are washed three times with wash buffer and covered
with glass slides using DuolinkII mounting medium (containing DAPI). It is imperative
to conduct all incubation steps in a wet chamber to prevent the samples from falling dry.
2.14. Gel analysis
Coomassie blue stained bands and resulting concentrations were determined using ImageJ
by comparison of a BSA dilution series with known concentrations. The resulting data
points serve as a basis to produce a line of best fit-equation, which can be used to estimate
the concentration of the virus in the sample.
2.15. Ligation
Amplicons received from mutagenesis PCR reaction (2.6) were previously phosphorylated
(Table 2.7) on the 5’ end to allow for ligation reaction to occur. The T4 ligase covalently
links the 5’- phosphate with the 3’-hydroxy group, which results in a cirular stretch of DNA




Table 2.7.: a) Phosphorylation reaction setup as performed for mutagensis reaction.
b) Ligation reaction setup, for circularization of linear plasmid amplicon from
mutagenesis PCR.
(a) Phophorylation reaction
Primer (100 µM) 0.9 µL
10× T4 PNK buffer A 0.9 µL
10 mM ATP 0.9 µL





10× ligase buffer 2 µL




To ensure that the virus sample tested in the IL-10 assay is endotoxin free, a reporter cell
line (THP-Xblue cells, A.3) was employed. The essay is based on the activation of NF-κB
by pattern recognition receptors (here, toll like receptor 4 (TLR4)). Upon activation of
the NF-κB pathway, the inducible gene Secreted embryonic alkaline phosphatase (SEAP)
is activated. SEAP is a truncated version of the human placental alkaline phosphatase
(PLAP) which was modified by removing the GPI (Glycophosphatidylinositol) anchor,
rendering it extremely heat stable and unaffected by inhibitor L-homoarginine. Upon
TLR4 triggering, SEAP is produced and secreted into the cellular supernatant from where
it can be harvested for testing.
THP-Xblue cells were thawed quickly at 37 oC in a water bath and resuspended in 15 mL of
THP-growth medium (A.8). To remove the excess of DMSO from the freezing media, cells
are centrifuged at 200-300 rcf for 5 min and old medium is aspirated. Cells are resuspended
in 1 mL of growth medium and added to a 25 cm2 cell culture flask containing an extra
5 mL of growth medium. Cells are growth at 37 oC in a CO2 incubator until they have
recovered and grow. Selection process was initiated by the addition of 200 µg
mL
of Zeocin ™
to THP-growth medium. Once under selective pressure, cells need to be passaged every
three days at 7 × 105 cells
mL
, not to exceed 2 × 106 cells
mL
. Cells are used at 1 × 106 cells
mL
for
testing the samples resuspended in growth medium. In a flat-bottom 96 well plate setup,
20 µL of sample are added to each well, followed by 180 µL of THP-cell-suspension. The
plate is incubated for 18-24 h at 37 oC in a CO2 incubator. After incubation, cells are
centrifuged to the bottom of the wells at 200-300 rcf for 5 min and 20 µL of supernatant is
added onto previously prepared 96-well-plate containing 180 µL of QUANTI-Blue™. The
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plate is incubated for 1-8 h at 37 oC and can is read out on a photometer at 620-655 nm.
2.17. Interleukin-10 assay
Interleukin-10 (IL-10) or human cytokine synthesis inhibitory factor (CSIF) is a an anti-
inflammatory cytokine encoded by the IL-10 gene, which is found downstream of several
cell signal pathways (Figure 2.4) mainly from patter recognition receptors. However, there
is also crosstalk between several signal transduction pathways. Mitogen activated protein
kinase pathway (MAPK) signaling pathway is also capable to induce IL-10 production
as it signals over RAF which is capable to phosporylate MEK.
Figure 2.4.:
Interleukin- 10 can be induced by Toll-like receptors (TLR) or other pathways
in macrophages and myeloid dendritic cells (DCs). Via the activation of
TLRs and their adapter moleculres, myeloid differentiation primary-repsonse
protein 88 (MYD88) and TRIF result in the activation of ERK1 and ERK2
(here: ERK), p38 and NF-κB pathways. The activation of these pathways
leads to IL-10 response of cells [40].
PERV-A/C, which binds to the human PERV-A receptor is also said to be an inducer
of an IL-10 response by peripheral blood mononucleated cells (PBMCs). These human
PBMCs were previously harvested from donors from the lab and have either been frozen
and thawed before use, or were freshly isolated and isolated using Ficoll-Paque centrifu-
gation in accordance with the protocol established by the manufacturer (A.8).
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Samples were previously analyzed using SDS polyacrylamide gels Coomassie blue stain-
ing to determine the size the amount of viral particles within the supernatant concentrate
using ImageJ. To inactivate and to make the viral isu-domain more accessible, to the
PMBCs, the samples undergo a 5 × freeze-thaw process, in which the viral particles are
disrupted [41]. A dilution series of duplicate samples was applied to observe the effect of
IL-10 induction of the samples. Additionally another set of identical duplicates was set up
with the addition of TAK-242 (A.8), a small-molecule inhibitor, which binds selectively
to TLR4, to silence the effects of residual LPS in the sample. TAK-242 was used at 5 µM
to completely circumvent activation of TLR4 [42].
On a 96-well-plate format, 3×106 PBMCs are seeded out and the sample is added at
the previously calculated concentration. The final volume of each well is 200 µL. The
plate is incubated at 37 oC in a CO2 incubator for 18-24 h.
A 96 well plate is prepared simultaneously by adding 100 µL of capture Antibody (A.1)
per well. The plate is sealed and incubated at 4 oC overnight.
After incubation, the wells are washed three times with washing buffer (A.2), the plate
is blocked for 1 hour at RT with assay diluent solution and then removed as previously
described. Samples have been added (100 µL) and incubated for 2 hours at RT. After
incubation period, samples are removed by washing five times. After the addition of work-
ing detector (Detection antibody + SAv-HRP reagent), the plate is sealed and incubated
for 1 hour at room temperature. A final wash of seven times is applied and 100 µL of
substrate solution (A.2) is added. After a final incubation of 30 min shielded from light,
the reaction is stopped by the addition of stop solution (A.2) and the plate is read at 450
nm and 570 nm.
2.18. Gibson assembly for Generation of PERV-A/B
hybrid
Gibson assembly is a molecular cloning technique which relies on homology of the end-
points of backbone and insert. T5 exonuclease degrade the ends of the amplicon on one
strand, producing sticky ends. When homology is present, the ends of both, backbone
and insert, will be compelmentary to each other allowing for annealing. A possible result-
ing gap is closed by polymerase activity and the nick is sealed via a T4 ligase. For the
20
2. Methods
purpose of this study Gibson Assembly® Master Mix (A.4) by New England Biolabs was
utilized. The master mix contains the above mentioned components. Additionally, chem-
ically competent cells are included (5-α E.coli) which have been used for transformation
according to the vendor-specific protocol.
I have identified flanking regions of PERV-A(42)-Env and PERV-B(33)-Env which
showed sufficient homology for Gibson assembly. These flanking regions serve as a tem-
plate for primer design. Env-amplifying primers are used on PERV-A(42) Env. Their
reverse complement serves as the primer pair for PERV-B backbone amplification. Due
to the large size of the PERV-B(33) genome, additional primer pairs were palced inside the
genome to minimize the amount of error (A.9). Intact and verified Env from PERV-A(42)
was amplified using Phusion Hot Start flex polymerase (A.4). Additionally, PERV-B(33)
backbone was amplified using primers described above. The resulting fragments were
verified (Figure 3.20) on a 1 % agarose gel and eluted with stratec gel extraction kit
(A.5).
Figure 2.5.: Outline of Gibson Assembly [43]
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3.1. Characterization of PERV-A(42)
To develop higher titers of neutralizing antibodies by mutating the immunosuppressive do-
main of PERV, site-directed mutagenesis, using the molecular clone PERV-A(42, (kindly
supplied by Prof. Dr. Ralf Tönjes, Paul Ehrlich Institut), was performed. This clone
served as the basis for the entire work and had to be verified for authenticity first. Several
steps were undertaken to verify the clone.
3.1.1. Characterization of the PERV-A(42) genome
First, the clone was analyzed by performing multiple restriction digests. The fragments
obtained were used for comparison with fragments from in silico digests of the clone’s
sequence (A.11). As the molecular clone contains a vector backbone, which may result in
extra bands, only fragments, which matched sizes within the 5’ and 3’ region of the clone
were used for analysis. By performing a restriction digest we showed that regions of the
clone, which are not part of the backbone vector can be verified using PstI and HindIII
(Figure 3.1).
Following this analysis, the clone was used for amplification of env using primers shown
in table 2.4 and PCR conditions as shown in table 2.2. The resulting amplicons had a size
of ≈2300 bp which is in accordance with the expected size (Figure 3.2). The resulting
fragment was used for amplification of env as previously described in section 2.4 using
primers as shown in table 2.4. The resulting apmlicon shows strong bands in the range
of ≈2300 bp as expected.
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Figure 3.1.: Electrophoretic analysis of fragments after digestion with PstI and HindIII
showed fragments not flanked by 3’ and 5’ regions including ≈3350 bp and
≈2332 bp fragments for PstI as well as ≈570 bp, ≈623 bp, ≈1011 bp, ≈1471
bp and ≈3250 bp for HindIII. Additional bands are the result of cutting of
cloning vector backbone.
Figure 3.2.: Amplification of the entire env of PERV-A(42) including two StuI sites on
the 5’ and 3’ end. Marker in lane 1 (GeneRuler 1 kb DNA Ladder, A.8 and
A.7) indicates clear fragment (Lane 2) at expected size (≈2.3 kb)
Part of the assessment included sequence analysis and comparison of the original PERV-
A(42) sequence as published under accession number (AJ133817) with sequence data
which was obtained from the Institute’s sequencing facility.
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The published amino acid sequence showed no difference when compared with our
sequenced data (Figure 3.3). No differences in the nucleotide sequence were identified.
However the last ten N-terminal amino acids were not sequenced. From the total length
of Env (660 amino acids), 650 amino acids were successfully sequenced, leading to a 98.48
% identity of the published sequence to provided molecular clone. It can be concluded
that both, the published sequence as well as the experimentally determined sequence are
identical.
Figure 3.3.: Sequence-comparison between the published PERV-A(42) sequence (acces-
sion №: AJ133817 ) and a consensus sequence (consensus depicted by gray
bars on top with sequence shown underneath) derived from multiple align-
ment from multiple sequencing steps to cover the entire Env of the molecular
clone. Although amino acids 650-660 were not sequenced, the entire Env
showed complete homology. Colors depicted serve to illustrate homology be-
tween amino acids.
3.1.2. Evidence that viral particles were produced
To verify if particles were produced by PERV-A(42), wild-type PERV/5o (a PERV-A/C
recombinant form [24]) (positive control), supernatant from uninfected cells (negative
control), and 293T transfected cells was continuously harvested and used for Western
blot analysis. PERV-A(42), produced proteins after transfection of 293T cells with the
same molecular weight as Gag (compare PERV-A/C), as shown by using Gag specific
antibodies (lane 7, Figure 3.4). Also PERV-A(42) transfected cells show clear signals for
Gag specific serum antibodies.
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Figure 3.4.: Western blot analysis, using anti-Gag/p27 (goat-serum# 30), anti-gp70 (goat-
serum# 62), and anti-p15E (goat-serum# 346). Sample PERV-A(42) 2000×
is a pooled sample constituted of supernatant of at least 3 consecutive weeks.
Most recently obtained PERV-A(42) was pelleted > 1 month after transfec-
tion (Lane 7). No bands can be observed anymore. No bands for gp70 as well
as for p15E can be seen, when compared to positive control (PERV-A/C).
293 T n.i. represents cellular supernatant harvested from non infected 293T
cell line and serves as a negative control. Denotations of 1000×, etc. refers
to factor by which supernatant was concentrated.
Western blot analysis showed Gag specific bands for PERV-A(42) which is in accordance
to the literature [11]. Other viral proteins like p15E and gp70 which are essential for
infectious particles were however not detected in the virus sample. Gp70 was however
present in the cell lysates. Interestingly, also the Gag signal disappeared analogously to
how many times cells were split. The viral particles were therefore not able to sustain
infection within 293T cells.
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3.1.3. Detection of viral proteins by immunofluorescence
To reinforce and confirm the current findings of the Western blot analysis, in situ im-
munofluorescence was used to track Env protein within a freshly transfected 293T cell.
Three different samples were analyzed. Firstly, transfection was carried out using PERV-
A(42). Additionally, PERV-B has shown in other Western blot analysis (not shown)
clear bands when probed with Gag specific antibodies (goat-serum # 30) and serves as
a positives control. Negative control was provided by non-infected 293T cells. No sig-
nal was detected from PERV-A(42) in immunofluorescent staining. The positive control
(PERV-B) clone demonstrated a clear signal, which was not observed in non-infected cells.
The results mirror previously obtained data from Western blot analysis in terms of Env
expression (Figure 3.5).
Figure 3.5.: Immunofluorescence analysis of PERV-A and PERV-B Env. Nuclei of the
cells have been stained using DAPI. The Env specific antibody is identical
with the antibody used for Western blot analysis. No signal can be detected
for PERV-A(42). PERV-B showed clear signals and therefore production of




3.1.4. Detection of viral particles by electron microscopy
Furthermore, transmission electron microscopy was performed to evaluate if newly PERV-
A(42)-transfected 293T cells produced particles. Confirming the missing of Env by earlier
Western blot analyses, no spikes protruding the viral envelope were seen on the virus
particle (Figure 3.6).
Figure 3.6.: Transmission electron microscopy photograph showing 293T cells with pro-
duced vial core-particles. No spikes were seen protruding through the viral
envelope.
3.1.5. Determination of the amount of protein
To measure the amount of produced viral proteins, purified virus samples were evaluated
via Coomassie blue stain. The amount of viral particles was estimated via the amount of
p27Gag found in the virus samples. A line of best fit was determined using a standard
BSA dilution series yielded equation 3.1. The amounts of p27Gag was estimated, leading
to the results shown in table 3.1. As the average number of Gag required to form a viral
particle can be estimated as only 40 % of the 5000 Gag-proteins that are the considered
maximum [44]. The amount of viral particles per µL was therefore determined applying
equation 3.2. The resulting number of viral particles is shown in table 3.1.




















Table 3.1.: Determination of the amount of virus within sample determined on the basis
of Coomassie blue staining with a BSA standard. Average number of particles
per µL is based on 2000 Gag proteins necessary to form a viral capsid [44].





5 PERV-A/C (1000 ×) 771.355 0.05 5.48× 104
6 PERV-B (1000 ×) 5105.154 1.18 1.32× 106
7 PERV-A/C (1000 ×) 793.113 0.05 6.11× 104
(a)
(b)
Figure 3.7.: a) Coomassie blue staining of the BSA standard at 4 ng in lane 1, 2 ng
in lane 2, 1 ng in lane 3, and 0.5 ng in lane 4. 10 µL PERV-A/C (1000×
concentrated) samples from two different dates were running in lanes 5 and
7. Lane 6 contained 10 µL of PERV-B sample (1000× concentrated). b)
Determining the amount of viral particles based on BSA plot, carried out at
4 ng, 2 ng, 1 ng, and 0.5 ng per lane. 4 ng reading was excluded because of
obvious saturation effects which distorted the signal strength.
Although PERV-A(42) was described in the literature as a fully infectious clone [18],
these findings were not confirmed here. The digestion pattern matches the supposed pat-
tern determined by virtual digests of the published sequence, the clone failed to replicate
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in cell culture, as ascertained by several Western blot analyses (Figure 3.4). Sequencing
of env did not show changes in the amino acid sequence of the used clone. As however env
seems fully intact, it can still be utilized for site-directed mutagenesis and the generation
of protein expression clones.
3.2. Generation of PERV mutants
To study the effects of mutations on the isu-domain in terms of cytokine release and
the production of neutralizing antibodies against PERV, several mutants were created
applying a back to back site-directed mutagenesis. Despite its inability to infect cells in
vitro, PERV-A(42) still serves as a good basis to apply such site-directed mutagenesis, as
its env gene was verified to be entirely intact.
3.2.1. Cloning of the env gene
The env fragment of PERV-A(42) was amplified using a Taq polymerase and cloned
into the pGEM®-T Vector system for growth in E.coli to obtain larger amounts for
site-directed mutagenesis. The Taq amplified env -fragment was cloned into the pGEM®-
T Vector (A.10), and the resulting construct was cleaved using restriction enzyme NotI
after successful transformation and isolation of plasmid DNA (for setup refer to table 2.1).
Electrophoretic analysis has confirmed the successful incorporation of the fragment which
was used for site-directed mutagenesis (Figure 3.8). The size of the amplified fragment
as well as the the fragment detected via restriction enzyme digest match the size of the
in silico cloning with its annotated NotI restriction digest site, which predicts a fragment





Figure 3.8.: a) Restriction digest and elecrophoretic analysis of Digest- pGEM®-T Vector
+ env shows two fragments at 3000 bp (vector backbone) as well as at 2300
bp (insert) (Compare with construct in figure 3.8. Clones 1 (lane 2), 4 (lane
4), 5 (lane 6), and 7 (lane 8) show the desired fragment and were sequenced
for further verification. b) Construct of pGEM®-T Vector including the
previously amplified env fragment (labelled: 62...2303 INSERT PERV-A env)
showing features of the backbone vector as well as NotI restriction sites, which
were used for verification-digests
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3.2.2. Site-directed mutagenesis of the env gene
In order to create mutant versions of env that contain mutations known to abrogate
cytokine release from PBMCs [45], site-directed mutagenesis was performed using back
to back PCR, with primers containing the desired mutations (Figure 3.9). Performing
PCR reaction yielded linear fragments containing the desired mutations. These DNA
fragments were isolated from the 1 % agarose gel using DNA extraction kit (Figure 3.9).
To improve the efficacy of the following transformation, a KpnI- digest was performed
prior to gel electrophoresis to reduce the number of unmutated template.
Figure 3.9.: Gel electrophoresis showing back to back site-directed mutagensis PCR with
their linear products for 3 mutations induced (Figure 3.10) as well as for the
remaining mutations (Figures 2.1 and 3.10). NotI cuts at multiple cloning site
in pGEM vector, effectively separating backbone and insert. Initial N=⇒A
mutations was performed using the quick change site-directed mutagenesis
kit (A.5) and shows the same band pattern after NotI-digest.
The ligated products were transformed into Z-cells and grown overnight on LB-Amp
agar plates at 37 oC. Several colonies were picked the next day for inoculation of 4 mL
LB+Amp broth. Due to no alteration in insert size or alteration of the insert itself,
no colony PCR was performed on the arising colonies. Plasmid DNA was recovered
using Invisorb® Spin Plasmid Mini Two (A.5) and quantified via Nanodrop (A.6). The
resulting isolated DNA was sequenced and analyzed for induced mutations, as well as
for randomly induced single base changes, due to amplification. This was accomplished
using the UGENE sequence analysis tool, published under the Gnu Public License (GPL).





Figure 3.10.: Mutations induced by back to back site-directed mutagenesis. Sequence
analysis was performed using UGENE. a) Reference amino acid sequence
is shown as first entry. Colored amino acids show homology to reference
sequence. Amino acid changes are indicated by initial amino acid =⇒
amino acid resulting from mutation. Three amino acids were changed
in the case of the 3 mutations. Colors depicted serve to illustrate homol-
ogy between nucleotides. Non-homologous nucleotides are depicted in white
compared to the reference sequence, which is shaded gray. A consensus se-
quence is depicted on the top and nucleotide homology is shown by gray
bars. b) The translated sequence of the base nucleotide sequence shown
above and the resulting mutations it contains on the amino acid level.
Several PERV-A(42)-env mutants were produced. Those mutants may serve as the
basis for further experiments and will ultimately be used in the production of higher titer
antibodies for the development of an improved PERV vaccine.
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3.3. Influence of PERV on cytokine release of human
PBMCs
In order to investigate the immunosuppressive properties of PERVs on human PBMCs
an IL-10 assay was performed. As IL-10 is a common immunosuppressive and anti-
inflammatory cytokine, which is usually produced by CD4+ cells (TH2 cells) as well as
macrophages and dendritic cells [46, 47]. IL-10 along with other cytokines, such as IL-
4, and IL-13 are known to downregulate microbicidal activities of macrophages, as well
as to reduce costimulation and downregulate the expression of major histocompatibility
complex (MHC) class II [47]. The exposure to human PBMCs is therefore a good tool to
estimate the immunosuppressive effect PERVs can have on the organism.
3.3.1. Characterization of virus sample
Since endotoxins can trigger TLR4 and result in the release of IL-10, prepared virus sam-
ples needed to be tested for endotoxin contamination to avoid false positives. Samples
were tested for endotoxin contamination via THP-Xblue cells (Engineered Human Re-
porter Monocytes) which carry a NF-κ-B inducible SEAP system to analyze activation
of toll like receptors. Previously virus samples were prepared via ultracentrifugation and
20 % sucrose-filtration. The resulting pellet was analyzed by via SDS-PAGE as well as
Western blot analysis (Figure 3.11). Additionally the amount of viral particles was de-
termined using equation 3.2. The resulting number of particles per µL is mentioned in
table 3.1.
Samples tested and used for the PBMC-based IL-10 assay did not show significant
contamination with endotoxin after adjusting the standard (Figure 3.12). The sample
was measured at three different time points. Similar results were obtained at all three
different time points (1h, 2h, and ≈16h post addition of QUANTI blue).
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Figure 3.11.: PERV-A/C used for endotoxin assay with THP-Xblue cells, as well as for
IL-10 release with PBMCs. Top portion show signal from anti Gag/p27
goat-serum (# 30) antibodies. Bottom portion shows signal from anti p15E
goat-serum (# 346)antibodies.
Figure 3.12.: Endotoxin assay employing THP-Xblue cells. The endotoxin standard is
shown on the left side. Standard was diluted in a 2-fold serial dilution.
PERV samples showed very low amounts of endotoxin. The PERV-A/C
pool was utilized for IL-10 assay. Error bars show ±1 standard deviation
[48].
3.3.2. Influence of PERV on IL-10 release
Effects of PERV-A/C on human PBMCs were evaluated using human PBMCs. The anti-
inflammatory cytokine interleukin-10 expression was measured by incubating PBMCs
with virus samples as described. To inhibit the activity of putative endotoxin induced
IL-10 expression, TAK-242, a TLR4 inhibitor was added (5 µM).
A very strong activation of IL-10 expression for samples not treated with TAK-242
inhibitor (blue) was observed. With decreasing amount of virus used, the effect decreased
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accordingly. TAK-242-inhibited samples showed IL-10 release for the highest concentra-
tion of virus-particles used. Here, with decreasing number of viral particles no more effect
on PBMCs was observed in terms of detectable IL-10 production (Figure 3.13). The
Figure 3.13.: PBMCs after addition of PERV-A/C. The amount of virus was estimated
(Table 3.1). Strong decrease in IL-10 release was observed for TAK-inhibited
samples.
difference in IL-10 release between the absence and presence of TAK-242 still needs to
be addressed in other experiments. What triggers the IL-10 release still observed in the
TAK-inhibited sample still also requires continued testing and further investigation. Fur-
thermore, the effect of TAK-242 as well as the time point at which it was added to the
samples could play a role.
3.4. Expression of wild-type and mutated Env protein
To circumvent the problem of having a non infectious molecular clone of PERV-A, a
second strategy was to measure Env protein effects on human PBMCs. For this purpose
amplified truncated fragments of env containing the desired mutations were generated. To
improve upon expression efficiency, an additional Kozak sequence was added via primer
modification to the 5’ end of the amplicon produced for cloning. The necessity to trun-
cate the protein arose from it’s transmembrane domain. Transmembrane domains are
hydrophobic regions within a protein, which hinder the secretion of the protein. Primers




3.4.1. Production of truncated env amplicon
To produces truncated versions of env, additional primer sets were used to amplify the
previously produced mutated env of PERV-A(42) to produce a truncated Env. Two sets
of forward primers were used to produce a truncated env with a Kozak sequence and one
was used to produce a truncated Env without a Kozak sequence. The resulting amplicons
are indistinguishable in size on a 1 % agarose gel (Figure 3.14).
Figure 3.14.: 1 % agarose gel analysis of truncated mutated env. Left side shows amplicons
without Kozak sequence. Right side shows amplicons with Kozak sequence.
Differences in sizes cannot be distinguished on agarose gel.
Additionally, we prepared a positive control of unmutated truncated Env with and
without Kozak sequence. Primers chosen are identical to those used for the amplification
of mutated Env-fragments (Figure 3.15).
Figure 3.15.: 1 % agarose gel of truncated Env. Left lane shows amplicons without Kozak
sequence. Right lane shows amplicons with Kozak sequence. Different am-
plicon sizes cannot be distinguished on agarose gel.
3.4.2. Cloning of amplicons into expression vector
To obtain a protein expression clone, fragments were cloned into pTarget™ -Vector System
(2.4). After transformation into E.coli (A.3) and overnight incubation, resulting colonies
were tested for successful insert via colony PCR (Figure 3.16). Positive clones were used
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for inoculation for plasmid isolation. To verify if the desired insertion was incorporated
in the right direction, additional probing via restriction enzyme digest was imperative.
(a)
(b) (c)
Figure 3.16.: a) Colony PCR of fragments containing Kozak sequence. b) and c) Colony-
PCR of fragments not containing Kozak sequence. Primers selected are
identical to primers selected for generation of truncated env fragment.
3.4.3. Verification of directional insertion of amplicons
To verify the proper insertion of the amplicon into the pTarget vector system, a restriction
enzyme digest was performed. Depending on the direction in which the fragment is
inserted, it will result in different size fragments from digestion, as the position of the
restriction enzyme site will change with respect to the backbone vector. Electrophoretic
analysis on a 1 % agarose gel has revealed several clones that show inserts in the right
orientation (Figure 3.17).
Figure 3.17.: Electrophoretic analysis of KpnI digest of pTarget-env clones. Direction-
independent cloning occurred as a result of TA cloning. Small band (≈ 500
bp) and large band (≈ 6 kb) represent successful orientation of insert.
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Mutated as well as unmutated inserts have a KpnI restriction site within their genome
located towards their 5’ end. The pTarget backbone vector has the same restriction site
at it’s 3’ end of its cloning site. When insertion occurred in the right direction, one small
fragment (≈ 500 bp) and one large fragment (≈6 kb) result from a KpnI digest. Several
clones carry the insert in the right direction and continued on by verifying their sequences
in two positions of their genome.
3.4.4. Characterization of pTarget-env clones
In order to verify if the amplified fragments were incorporated into the expression vector
without any additional errors, the immunosuppressive domain as well as the translational
start site of each clone was sequenced. Sequence analysis confirmed the successful gener-
ation of six protein-expression clones (Figure 3.18).
Figure 3.18.: Sequence alignment showing start codon of various clones with amino acid
change alluded to in their names. Separated by dashed line mutations base
changes are illustrated by non-colored boxes, as compared to reference se-
quence (wild-type).
Several expression clones were created. Among those clones is also a control construct
(28-wild-type(Positive-Control)), which contains unmutated and truncated PERV-A(42)-
env. Out of the six successfully created expression clones, two carry a Kozak sequence to
enhance translation. Amplicons were created with primers not including the transmem-
brane domain, preventing attachment in the cell membrane and therefore facilitating cell
exit. The final assortment of expression clones can be seen in figure 3.19.
At this point it was not verified if and to what amounts these clones are able to produce
protein. Hence additional transfections with SDS-PAGE gel electrophoresis will have to
be conducted in the future. Also these constructs may prove to offer new insights in terms
of cytokine release from human PBMCs.
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Figure 3.19.: Isu domain of expression clones created with pTarget Vector system.
3.5. Generation of replication-competent hybrid
PERV-A/B
To develop an alternative route and to counteract the problem of a non-replicative PERV-
A(42), transplanting PERV-A(42)-env into replication-incapable PERV-B(33) clone was
decided. PERV-B(33) is know to have a defective start codon in env, which is the reason
for its inability to produce infectious particles [11]. However, by replacing PERV-B(33)
env, with the full length PERV-A(42) env could restore infectious properties. To still
be able to use the prepared mutations, the env transplant was performed using Gibson
assembly. Several fragments were produced using PCR (Figure 3.20). These fragments
were used in Gibson assembly, as described in Figure 2.5.
Figure 3.20.: Fragments produced using PCR. Lane 2 shows amplified env from PERV-
A(42). Lane 3 and 4 show the amplified parts of the PERV-B(33) backbone.
All three fragments were used in the Gibson assembly.
Efforts so far were unsuccessful to re-assemble PERV-B(33) backbone while incorpo-
rating PERV-A(42)-env.
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Xenotransplantation is aiming on closing an ever wider-growing gap between the growing
demand of donor organs in an aging population and the decreasing number of donors.
Porcine organs seem to be a good candidate due to their relative similar size as well
as similar physiological conditions in pigs such as blood pressure. Other issues are well
known and documented, such as hyperacute rejection. Strategies to overcome these prob-
lems are known and applied.
It is therefore becoming more and more important to understand the impact of endoge-
nous factors on the health of a potential organ recipient. Like all retroviruses, porcine
endogenous retroviruses could pose a threat to public health. Permanent exposure to
released viral particles could lead to immunosuppression. The development of viruses
mutated in the isu-domain and an improved vaccine based on these mutants was there-
fore the focus of this study. It has been shown that HIV, HERV-K (human endogenous
retrovirus-K) and other retroviruses have immunosuppressive properties that can be ab-
rogated with single amino acid substitutions in several sites in their immunosuppressive
domains [18, 33–36, 45].
4.1. PERV-A(42)
The declared goal of this project was to perform an immunization study with mutated
forms of the received PERV. For this, the PERV-A(42) clone from Prof. Dr. Ralf Tönjes
from the Paul Ehrlich Institute, Langen, Germany was used. This clone was supposed
to be infectious and therefore able to sustain itself in 293T cells in vitro. It was shown
in the experiments that this molecular clone was not replication-competent. Figure 3.4
illustrates a previously established positive control consisting of PERV-A/C used in this
research group. This positive control is maintained as infectious particles within a 293T
cell line and is not available as a molecular clone. It has been generated by co-infectiion
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of porcine cells with PERV-A and PERV-C in vivo, to create a recombinant PERV-A/C
strain [24, 25]. This strain was shown to be highly replication-competent in human 293T
cells in vitro. This is possible despite the non-human-cell-tropic nature of PERV-C. The
interaction partner of PERV-A/C is the human PERV-A receptor (HuPAR) [49].
As described [11], Gag protein could be measured for PERV-A(42)-transfected cells in
vitro several days after transfection was performed. Those findings was confirmed as part
of this study. The effect is however fleeting and vanishes overtime, as cells were split and
the viral DNA became more dilute. Finally, no more Gag was detected anymore in the
harvested supernatant (Figure 3.4). There was reason to believe that the PERV-A(42)
therefore has a defect in it’s env gene. The possibility of frameshift mutations, random
deletions, and nonsense mutations had to be investigated. Possible causes for such events
could be subcloning into a sequencing vector or re-transformation and random recombi-
nation due to bacterial recombinases. Also, preceeding PCR amplifications, may have
caused point mutations leading to a non-infectious clone. As sequencing data revealed,
the clone used for transfection of 293T cells shows a sequence identical to its published
reference (accession №: AJ133817). Since Western blot analysis did reveal that Gag pro-
tein is produced, so called Gag-particles were formed which do not posses the ability to
infect 293T cells in vitro. To elucidate if any virus particles were formed after transfec-
tion, transmission electron microscopy was employed. Photographs show a virus-particle
without visible Env protrusions sticking out from the viral envelope.
Another possibility was that faulty cleavage of Env was responsible for the absence
of visible spikes of the virus. Such cleavage errors may result in a malformed Env that
could render the virus unable to infect new cells and would therefore stop it’s progression
[11, 50]. While very small amounts of Env were detected by Western blot analysis in
cell lysates produced from freshly transfected 293T cells, no Env was detected, as verified
by immunofluorescent imaging (Figure 3.5) supporting the findings from the electron
microscopy. Therefore other explanations are needed to elucidate how the translation of
the env region has come to a halt. Yet this scenario can still not be completely ruled
out as Env may simply be inaccessible during processing in the Golgi apparatus, and
degraded when not cleaved properly. Nevertheless, it is feasible to entertain other ideas.
One possible explanation would be an error within the splicing donor or splicing acceptor
site. The resulting transcript would therefore only contain a polyprotein of Gag-Pol-Env
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[50] that was not shown by Western blot analysis. The polyprotein would not participate
in forming infectious particles and is possibly degraded after synthesis. This could result
in a particle consisting only of core proteins as well as a non-detectable poly-protein
(lysate and supernatant).
4.2. Endotoxin and IL-10 assays
When IL-10 assays were performed, effects on the release of IL-10 in human PBMCs
were determined (Figure 3.13). As IL-10 release can be triggered by several stimuli [40],
other factors that might activate such pathways need to be investigated further before
any conclusions are made. The samples were tested for endotoxin, which is known to be
able to activate TLR4 via CD14 binding. At the end of the TLR4 signaling-cascade IL-10
production was induced. The tests showed that samples used for the IL-10 assay were very





significant change in endotoxin levels (significant change = p < 0.05) as their difference
did not exceed two standard deviations (2σ = 95.45 % ≈ 0.95). This is in accordance with
findings also published by Rylander, 2002 who states that normal endotoxin concentration





Those low endotoxin levels found in the samples were not disregarded (Figure 3.12).
To circumvent any endotoxin dependent activation of TLR4, and therefore false posi-
tive IL-10 release readings, TAK-242-inhibitor was added to the samples to block the
LPS-dependent activation of TLR4 [42](final concentration 5 µM). 2.6× 106 particles (40
µL of 1000× virus sample) were used for as the highest concentration in the endotoxin
assay. Despite the addition of TAK-242, signal could still be confirmed although sig-
nificantly lower than without the addition of the inhibitor (Figure 3.13). Previously a
dose-dependent activation of PBMCs and a subsequent production of IL-10 cytokine was
demonstrated [45]. HIV-1, which also contains an isu peptide that shows great homology
with other isu peptides, found in retroviruses [35], was used to illicit an IL-10 response
by PBMCs in previously performed experiments [45]. In these previous investigations, a
strong release of IL-10 was observed when PBMCs were incubated with the isu-peptide
[35, 45]. This is however not in accordance with the findings of this study with PERV.
While a small variance was found between negative control (standard growth medium)
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and virus sample, it does not compare to the findings of the immunosuppressive effect
of HIV-1, or HERV-K published earlier [35, 45]. Also, experiments that were conducted
simultaneously to the PERV-study, showed that newly prepared wild-type pNL as well as
mutated pNL did not induce any release of IL-10 by PBMCs [Data not published].
As TAK-242-inhibitor completely blocks TLR4 signal transduction, the remaining IL-
10 production observed in the sample is object to discussion. The so called isu domain
which has been shown previously to have immunosuppressvie effects [35, 45, 51] could
have induced IL-10 production in PBMCs. However, no receptor for the isu-protein was
identified to this date.
There has been little evidence that indicates that PERV-A/C was able to induce IL-10
release in human PBMCs. Little release of IL-10 could still be observed after blocking
TLR4 using TAK-242 inhibitor. To obtain more reliable results, the remaining levels of
endotoxin in the samples need to be lowered. Ideally, no additional TAK-242 inhibitor
should be added. Although TAK-242 was used at 5 µM (maximum working concentration)
it was not incubated with PBMCs prior to the addition of the samples as suggested by the
available literature [52]. Given the data at hand, it can be deduced that any remaining
IL-10 release of PBMCs will vanish with longer exposure to the inhibitor.
4.3. Generation of a PERV-A/B hybrid and protein
expression
Efforts were undertaken to create a PERV-A/B hybrid by excising the env region of
PERV-A(42) and cloning it into a PERV-B(33) backbone. This backbone is itself not
replication competent as it lacks a functional env [11]. It was however demonstrated above
that PERV-A(42)-env is error free, but not expressed when the viral clone was used for
transfection, as shown by in situ immunofluorescence (Figure 3.5). However, generating
a hybrid clone from two different non-working clones offers several challenges. Firstly, the
length of the genome itself represents problems. Producing error free amplicons requires
high fidelity polymerases with proof-reading ability. However, complicated templates such
as long terminal repeats with GC rich regions that are hard to verify pose an additional
burden on the process [53]. First attempts to generate whole-backbone-amplicons for the
insertion of PERV-A(42)-env were therefore unsuccessful. An alternative strategy was
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to amplify the PERV-B(33) backbone in two steps leaving four homologous regions to
be ligated during Gibson assembly. Amplification of fragments was successful and clear
bands were observed as seen in figure 3.20. However efforts have so far been unsuccessful
to assemble the various fragments after gel extraction via Gibson assembly. Possible
reasons could be in the degradation of DNA over time, as these fragments were not
used immediately. Another reason may be a too short extension period for the long
(6 kb) amplicon. This may result in variable-length fragments that could be observed
as slightly thicker bands on a 1 % agarose gel (Figure 3.20). At last, genetic material
recovered may have been contaminated with salts or other organic compounds due to the
elution process from the agarose gel. To circumvent this possibility in the future and to
improve cloning efforts, a DpnI digest could be used to digest methylated template DNA
only leaving intact amplicons. This is possible, as no extra bands were obtained. The
resulting solution could then be cleaned via PCR-clean up kit (Invisorb® DNA CleanUp
A.5) to minimize the effect of residual ethanol and salts for downstream applications.
It seems that a viable system was found to bypass the problem, with all tools in place
to create a replication competent clone, provided the constructs given allow for proper
assembly of the virus. Similarly the production of protein expression vectors, wild type
and mutated, has revealed additional problems, such as long length amplicons and good
efficiency in terms of protein secretion. The employment of a well functioning site-directed
mutagenesis technique as well as the proper incorporation of the mutated fragments into
the expression vector is crucial for success. Additionally, Env contains a transmembrane
domain, which anchors the protein within the membrane of a cell, making it impossible to
isolate sufficient amounts of Env from the supernatant of cells in cell culture(Figure 2.3).
In order to prevent this from happening the env gene needed to be truncated in a way
that it’s transmembrane domain was cleaved out and it could be readily secreted from the
cell. Otherwise only harvesting of cell-lysate, which contains remnants of cellular debris,
would have been possible. Such debris (e.g. fibrinogen and heparan sulfate) may be a
reason for false readings when conducting IL-10 assays as it can also trigger TLR4 [54,
55].
Several clones containing mutations described in section 3.4.1 were produced. However,
not all of the created mutants were incorporated into the expression vector. Directionality
of the inserts was reversed in the majority of clones rendering them useless for protein ex-
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pression. For future applications, this process could be improved by employing directional
cloning techniques such as Gibson assembly as previously described (Section 2.18).
Until now, these clones have not been tested for secretion in vitro. Only small amounts
of the clones were produced to verify the incorporated changes as well as the translational
start-site modifications. It was part of this effort to keep the protein as much in a native
form as possible. Hence, attaching affinity-tags was not a viable option, which could have
yielded higher results when purifying protein over a metal-matrix-column. Lower amounts
are therefore expected to be present after harvested from supernatant and would have to
be quantified employing the method described earlier (Section 3.1.5).
4.4. Outlook
Future work should be directed to the generation of replication-competent wild-type and
mutated PERV as basis for the development of a better vaccine. This also includes
the completion of the PERV-A/B hybrid as well as full characterization of the protein
expression clones. Further assays to observe IL-10 release can be conducted to verify the
immunosuppressive properties of wild-type PERV-A/C as well as wild-type PERV-A/B.
Furthermore, more stringent care needs to be taken to reduce endotoxin contamination.
The use of endotoxin-free water, as well as the use of chemicals designated only for IL-10
assays and the production of virus samples should be imperative and could reduce the
risk of contamination. Also, the use of air-conditioners which could potentially act as a
endotoxin-distribution systems should be considered. Devices with air filters should be
maintained regularly and used air-filters should be replaced on a regular bases [48].
An entirely different route could be taken by establishing a molecular clone of the
recombinant PERV-A/C virus, which is currently only available in the form of viral par-
ticles. The establishment of such a clone would guarantee a more reliable standard as it
can more easily be replicated by de novo transfection. This would ensure the identity of
the clone, as the virus may change over time due to accumulating mutations. Also, efforts
could be undertaken to isolate PERV-A/C-env via reverse transcription or via amplifica-
tion of proviral DNA. It is difficult to determine which technique would offer better results
in terms of virus infectivity. Reverse transcription of viral RNA would ensure that only
genetic material from viruses that actually form infectious particles, was used. However,
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it cannot be guaranteed that even those viral particles contain the same genetic material
that codes for it’s proteins. This is due to the fact that multiple copies of proviral DNA
from different in vitro-infections are present within the host-cell’s genome. Other retro-
viruses like HIV-1 for instance incorporate an average of 50 copies of proviral DNA into
the host-cell’s genome (CD4+ Cell) [56]. This also explains why, isolating proviral DNA
is not neccessarily going to yield infectious particles. As a comparison, the fraction of
infectious particles in HIV ranges from 50 % to as little as 1 % [57]. Similar fractions can
probably be expected for PERVs. This would imply that trying to develope a full clone,
as well as trying to isolate a functioning env would be unsuccessful in most cases.
Lastly wild-type and mutated p15E from both, PERV-A/B hybrid and PERV-A/C will
be expressed, purified and tested in immunosppressive properties as well as for immuniza-
tion experiments. With both PERVs available as a molecular clone it can be accurately
determined that the virus is in an unmutated form, as otherwise mutations may accu-
mulate over time in cell culture, due to ongoing replication. Deviations on the effect of
antibody titer as well as IL-10 production from PBMCs due to induced mutations are
therefore characterized on a more reliable basis.
4.5. Conclusion
To establish a solid basis for future trials and the successful development of an improved
vaccine against PERV further testing and the establishment of a replication-competent
molecular clone are of importance. Additionally, to reliably demonstrate the immuno-
suppressive effect of the isu peptide, the produced wild-type and mutated proteins, have
to be characterized and tested in IL-10 assays. Those mutants will serve as the basis for





Human IL-10 ELISA Set Vendor: BD OptEIA™
Capture antibody, detection antibody, streptavidin-HRP-
standards, Standard Range 7.8 - 500 pg
mL
Rabbit anti goat HRP (detection Ab) Vendor: Dako,
Cat. №: 0449




Anti Gag In- house produced antibody from Goat (Ziege)30
Anti Env In- house produced antibody from Goat (Ziege)62
Anti p15E In- house produced antibody from Goat (Ziege)346
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A. Appendix
A.2. Buffers and Solutions
Name Content
Annode buffer Tris (0.2M), final pH (with HCl): 8.9
Antibodi dilution buffer (IF) 5 % BSA (bovine serum albumin) in PBS
Blocking Buffer (IF) 5 % BSA grade V,
2 % chicken albumin, PBS
Cathode buffer Tris (0.1M), Tricine (0.1M), 0.1 % SDS, final pH: 8.25
Coomassie R250 45 % Methanol (reagent grade), 10 % Glacial acetic acid
45 % Water, 3 g
L
Coomassie Brilliant Blue R250
Destaining solution 50 % H2O, 40 % methanol, 10 % acetic acid
IL-10 Substrate Solution Tetramethylbenzidine and Hydrogen Peroxide
Alternatively: BD Pharmingen™ TMB substrate reagent set
Mountin Medium 90 % glycerol, 10 % PBS (with 1 % p-phenylenediamine)
Cat.№: 555214
NP40- cell lysis buffer (2 ×) 100 mM Tris-HCl, pH 8.0 , NaCl : 300 mM,
NP-40 : 2 %, EDTA : 10 mM
IL-10 Assay Diluent PBS + 10 % Fetal bovine serum (pH 7)
IL-10 Coating Buffer 0.1 M Sodium Carbonate, pH: 9.5 7.13g NaHCO3, 1.59g
Na2CO3, q.s. to 1 L, pH to 9.5 with 10 N NaOH
IL-10 Stop Solution 1 M H3PO4 or 2 N H2SO4
SDS-PAGE gel buffer Tris (3M), 0.3 % SDS, final pH (with HCl): 8.45
Transfer buffer Tris (48mM), Glycine (39mM), Methanol 20 %, SDS (0.03 %)
ELISA wash buffer PBS + 0.05 % tween-20
Wash Buffer (IF) 0.1 % Tween®-20 in PBS
A.3. Cells used
Component Additional information
JM109 (E.coli) Vendor: Zymo Research, Catalog №T3001 & T3002
HEK 293T Human Embryonic Kidney Cells
Contains SV40 Large T-antigen






Fast Digest 10× Green Buffer Supplied with Fast digest enzymes,
Vendor: Thermo Scientific
Fast Digest HindIII Vendor: Thermo Scientific
Catalogue №FD0504 & FD0505
Fast Digest PstI Vendor: Thermo Scientific
Catalogue №FD2224
Fast Digest EcoRI Vendor: Thermo Scientific
Catalogue №FD0274
Fast Digest KpnI Vendor: Thermo Scientific
Catalogue №FD0524
Fast Digest NotI Vendor: Thermo Scientific
Catalogue №FD0594
Fast Digest StuI Vendor: Thermo Scientific
Catalogue №FD0424
GoTaq® Green Master Mix Vendor: Promega,
Catalogue №M712
Phusion® Hot Start Flex Vendor: New England Biolabs
DNA Polymerase Catalogue №M0535S,
Contains also: Phusion® HF Buffer (5×),
Phusion® GC Buffer Pack(5×),





BigDye® Direct Cycle Sequencing Kit Vendor: LifeTechnologies
Cat.№: 4458689, 4458687, 4458688
GoTaq® Green Master Mix Vendor: Promega
Cat. №M7121, M7122, M7123
Pierce ECL Western Blotting Substrate Vendor: Thermo Scientific
Cat. №: 32106, 32209, 32109
pGEM®-T Easy Vector System I Vendor: Promega
Cat.№A1360, A1360





Invisorb® Spin Plasmid Mini Two Vendor: Stratec,
LOT: AG130010
Invisorb® Spin DNA Extraction Kit Vendor: Stratec,
Cat.№1020110300
Invisorb® DNA CleanUp Vendor: Stratec,
Cat.№1020400200




Centrifuge Vendor: Eppendorf, Model: 5810 R
Bench top centrifuge Vendor: Eppendorf, Model: Centrifuge MiniSpin®
High speed Centrifuge Vendor: Beckman Coulter, Model: Optima L-100K,
High speed Centrifuge
Cell Culture Centrifuge Vendor: Heraeus, Model: Megafuge 1.0R
Imaging system Vendor: INTAS GmbH, Model CHEMOCAM Imager 3.2
Midiprep System Vendor: Promega, Cat№: A2490
Cell Strainer Vendor: Sartorius Stedin, Size: 45 µL
Shaking incubator Vendor: Infors HT, Model: Ectotron




(a) GeneRuler 1 kb DNA Lad-
der
(b) GeneRuler DNA Ladder
Mix- Thermo Scientific
(c) PageRuler Prestained Pro-
tein Ladder- 10 to 170 kDa
(d) peqGOLD Protein
Marker II - 10 to 200 kDa




A.8. Media and reagents
Comopnent Additional information
Standard Medium 450 mL of DMEM (Vendor:)
5 mL Ultraglutamine
50 mL Fetal Calf Serum (FCS)
5 mL Antibiotics (Penicillin 10000 U/mL,
Streptomycin 10000 µg/mL)
5 mL Vitamins
Bacterial Medium Standard LB + Ampicillin (final: 100 µg
mL
)
Ficoll-Paque PLUS Vendor:formerly Amersham bioscience,
General Electric Healthcare,
Cat.№: 17-1440-02
cOmplete- protease inhibitor mix Vendor: Roche, Cat.№: 04693116001
QUANTI-Blue™ Vendor: Invivogen, Cat.№: rep-qb1, rep-qb2
TAK-242 TLR4 inhibitor Vendor: Invivogen
Cat.№: tlrl-cli95






glucose, 10 mM HEPES
and 1.0 mM sodium pyruvate)
with 10 % heat-inactivated fetal bovine serum
(30 min at 56 oC),
100 mg
mL





Transfection reagent TransIT®-293 Transfection reagent
Vendor: Mirus, Cat№: MIR 2700, 2704, 2705, 2706
DNA Marker Name: GeneRuler 1 kb DNA Ladder
Vendor: Thermo Scientific
Protein sample loading buffer Novex® Tris-Glycine SDS Sample Buffer





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.2.: pCR®2.1-TOPO® 3.9 kb map.
X
A. Appendix
Figure A.3.: 3015bp pGEM®-T Easy Vector used in cloning applications.





A.11.1. PERV-A(42): Accession number: AJ133817
>gi|6688947|emb|AJ133817.1| Porcine endogenous retrovirus type C










































































































































A.11.2. PERV-B(33): Accession number: AJ133816.1
>gi|6688945|emb|AJ133816.1| Porcine endogenous retrovirus type C











































































































































A.11.3. Multiple sequence alignment with PERV-A(42)-env
Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
1 M M . .
2 H H . .
3 P P . .
4 T T . .
5 L L . .
6 S S . .
7 R R . .
8 R R . .
9 H H . .
10 L L . .
11 P P . .
12 I I . .
13 R R . .
14 G G . .
15 G G . .
16 K K . .
17 P P . .
18 K K . .
19 R R . .
20 L L . .
21 K K . .
22 I I . .
23 P P . .
24 L L . .
25 S S . .
26 F F . .
27 A A . .
28 S S . .
29 I I . .
30 A A . .
31 W W . .
32 F F . .
33 L L . .
34 T T . .
35 L L . .
36 S S . .
37 I I . .
38 T T . .
39 P P . .
40 Q Q . .
41 V V . .
42 N N . .
43 G G . .
44 K K . .
45 R R . .
46 L L . .
47 V V . .
48 D D . .
49 S S . .
50 P P . .
51 N N . .
52 S S . .
53 H H . .
54 K K . .
55 P P . .
56 L L . .
57 S S . .
58 L L . .
59 T T . .
60 W W . .
61 L L . .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
63 T T . .
64 D D . .
65 S S . .
66 G G . .
67 T T . .
68 G G . .
69 I I . .
70 N N . .
71 I I . .
72 N N . .
73 S S . .
74 T T . .
75 Q Q . .
76 G G . .
77 E E . .
78 A A . .
79 P P . .
80 L L . .
81 G G . .
82 T T . .
83 W W . .
84 W W . .
85 P P . .
86 E E . .
87 L L . .
88 Y Y . .
89 V V . .
90 C C . .
91 L L . .
92 R R . .
93 S S . .
94 V V . .
95 I I . .
96 P P . .
97 G G . .
98 L L . .
99 N N . .
100 D D . .
101 Q Q . .
102 A A . .
103 T T . .
104 P P . .
105 P P . .
106 D D . .
107 V V . .
108 L L . .
109 R R . .
110 A A . .
111 Y Y . .
112 G G . .
113 F F . .
114 Y Y . .
115 V V . .
116 C C . .
117 P P . .
118 G G . .
119 P P . .
120 P P . .
121 N N . .
122 N N . .
123 E E . .
124 E E . .
125 Y Y . .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
127 G G . .
128 N N . .
129 P P . .
130 Q Q . .
131 D D . .
132 F F . .
133 F F . .
134 C C . .
135 K K . .
136 Q Q . .
137 W W . .
138 S S . .
139 C C . .
140 I I . .
141 T T . .
142 S S . .
143 N N . .
144 D D . .
145 G G . .
146 N N . .
147 W W . .
148 K K . .
149 W W . .
150 P P . .
151 V V . .
152 S S . .
153 Q Q . .
154 Q Q . .
155 D D . .
156 R R . .
157 V V . .
158 S S . .
159 Y Y . .
160 S S . .
161 F F . .
162 V V . .
163 N N . .
164 N N . .
165 P P . .
166 T T . .
167 S S . .
168 Y Y . .
169 N N . .
170 Q Q . .
171 F F . .
172 N N . .
173 Y Y . .
174 G G . .
175 H H . .
176 G G . .
177 R R . .
178 W W . .
179 K K . .
180 D D . .
181 W W . .
182 Q Q . .
183 Q Q . .
184 R R . .
185 V V . .
186 Q Q . .
187 K K . .
188 D D . .
189 V V . .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
191 N N . .
192 K K . .
193 Q Q . .
194 I I . .
195 S S . .
196 C C . .
197 H H . .
198 S S . .
199 L L . .
200 D D . .
201 L L . .
202 D D . .
203 Y Y . .
204 L L . .
205 K K . .
206 I I . .
207 S S . .
208 F F . .
209 T T . .
210 E E . .
211 K K . .
212 G G . .
213 K K . .
214 Q Q . .
215 E E . .
216 N N . .
217 I I . .
218 Q Q . .
219 K K . .
220 W W . .
221 V V . .
222 N N . .
223 G G . .
224 I I . .
225 S S . .
226 W W . .
227 G G . .
228 I I . .
229 V V . .
230 Y Y . .
231 Y Y . .
232 G G . .
233 G G . .
234 S S . .
235 G G . .
236 R R . .
237 K K . .
238 K K . .
239 G G . .
240 S S . .
241 V V . .
242 L L . .
243 T T . .
244 I I . .
245 R R . .
246 L L L .
247 R R R .
248 I I I .
249 E E E .
250 T T T .
251 Q Q Q .
252 M M M .
253 E E E .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
255 P P P .
256 V V V .
257 A A A .
258 I I I .
259 G G G .
260 P P P .
261 N N N .
262 K K K .
263 G G G .
264 L L L .
265 A A A .
266 E E E .
267 Q Q Q .
268 G G G .
269 P P P .
270 P P P .
271 I I I .
272 Q Q Q .
273 E E E .
274 Q Q Q .
275 R R R .
276 P P P .
277 S S S .
278 P P P .
279 N N N .
280 P P P .
281 S S S .
282 D D D .
283 Y Y Y .
284 N N N .
285 T T T .
286 T T T .
287 S S S .
288 G G G .
289 S S S .
290 V V V .
291 P P P .
292 T . T .
293 E . E .
294 P . P .
295 N . N .
296 I . I .
297 T . T .
298 I . I .
299 K . K .
300 T . T .
301 G . G .
302 A . A .
303 K . K .
304 L . L .
305 F . F .
306 S . S .
307 L . L .
308 I . I .
309 Q . Q .
310 G . G .
311 A . A .
312 F . F .
313 Q . Q .
314 A . A .
315 L . L .
316 N . N .
317 S . S .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
319 T . T .
320 P . P .
321 E . E .
322 A . A .
323 T . T .
324 S . S .
325 S . S .
326 C . C .
327 W . W .
328 L . L .
329 C . C .
330 L . L .
331 A . A .
332 S . S .
333 G . G .
334 P . P .
335 P . P .
336 Y . Y .
337 Y . Y .
338 E . E .
339 G . G .
340 M . M .
341 A . A .
342 R . R .
343 G . G .
344 G . G .
345 K . K .
346 F . F .
347 N . N .
348 V . V .
349 T . T .
350 K . K .
351 E . E .
352 H . H .
353 R . R .
354 D . D .
355 Q . Q .
356 C . C .
357 T . T .
358 W . W .
359 G . G .
360 S . S .
361 Q . Q .
362 N . N .
363 K . K .
364 L . L .
365 T . T .
366 L . L .
367 T . T .
368 E . E .
369 V . V .
370 S . S .
371 G . G .
372 K . K .
373 G . G .
374 T . T .
375 C . C .
376 I . I .
377 G . G .
378 M . M .
379 V . V .
380 P . P .
381 P . P .





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
383 H . H H
384 Q . Q Q
385 H . H H
386 L . L L
387 C . C C
388 N . N N
389 H . H H
390 T . T T
391 E . E E
392 A . A A
393 F . F F
394 N . N N
395 R . R R
396 T . T T
397 S . S S
398 E . E E
399 S . S S
400 Q . Q Q
401 Y . Y Y
402 L . L L
403 V . V V
404 P . P P
405 G . G G
406 Y . Y Y
407 D . D D
408 R . R R
409 W . W W
410 W . W W
411 A . A A
412 C . C C
413 N . N N
414 T . T T
415 G . G G
416 L . L L
417 T . T T
418 P . P P
419 C . C C
420 V . V V
421 S . S S
422 T . T T
423 L . L L
424 V . V V
425 F . F F
426 N . N N
427 Q . Q Q
428 T . T T
429 K . K K
430 D . D D
431 F . F F
432 C . C C
433 V . V V
434 M . M M
435 V . V V
436 Q . Q Q
437 I . I I
438 V . V V
439 P . P P
440 R . R R
441 V . V V
442 Y . Y Y
443 Y . Y Y
444 Y . Y Y
445 P . P P





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
447 K . K K
448 A . A A
449 V . V V
450 L . L L
451 D . D D
452 K . K K
453 Y . Y Y
454 D . D D
455 Y . Y Y
456 R . R R
457 Y . Y Y
458 N . N N
459 R . R R
460 P . P P
461 K . K K
462 R . R R
463 E . E E
464 P . P P
465 I . I I
466 S . S S
467 L . L L
468 T . T T
469 L . L L
470 A . A A
471 V . V V
472 M . M M
473 L . L L
474 G . G G
475 L . L L
476 G . G G
477 V . V V
478 A . A A
479 A . A A
480 G . G G
481 V . V V
482 G . G G
483 T . T T
484 G . G G
485 T . T T
486 A . A A
487 A . A A
488 L . L L
489 I . . I
490 T . . T
491 G . . G
492 P . . P
493 Q . . Q
494 Q . . Q
495 L . . L
496 E . . E
497 K . . K
498 G . . G
499 L . . L
500 S . . S
501 N . . N
502 L . . L
503 H . . H
504 R . . R
505 I . . I
506 V . . V
507 T . . T
508 E . . E
509 D . . D





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
511 Q . . Q
512 A . . A
513 L . . L
514 E . . E
515 K . . K
516 S . . S
517 V . . V
518 S . . S
519 N . . N
520 L . . L
521 E . . E
522 E . . E
523 S . . S
524 L . . L
525 T . . T
526 S . . S
527 L . . L
528 S . . S
529 E . . E
530 V . . V
531 V . . V
532 L . . L
533 Q . . Q
534 N . . N
535 R . . R
536 R . . R
537 G . . G
538 L . . L
539 D . . D
540 L . . L
541 L . . L
542 F . . F
543 L . . L
544 K . . K
545 E . . E
546 G . . G
547 G . . G
548 L . . L
549 C . . C
550 V . . V
551 A . . A
552 L . . L
553 K . . K
554 E . . E
555 E . . E
556 C . . C
557 C . . C
558 F . . F
559 Y . . Y
560 V . . V
561 D . . D
562 H . . H
563 S . . S
564 G . . G
565 A . . A
566 I . . I
567 R . . R
568 D . . D
569 S . . S
570 M . . M
571 S . . S
572 K . . K
573 L . . L





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
575 E . . E
576 R . . R
577 L . . L
578 E . . E
579 R . . R
580 R . . R
581 R . . R
582 R . . R
583 E . . E
584 R . . R
585 E . . E
586 A . . A
587 D . . D
588 Q . . Q
589 G . . G
590 W . . W
591 F . . F
592 E . . E
593 G . . G
594 W . . W
595 F . . F
596 N . . N
597 R . . R
598 S . . S
599 P . . P
600 W . . W
601 M . . M
602 T . . T
603 T . . T
604 L . . L
605 L . . L
606 S . . S
607 A . . A
608 L . . L
609 T . . T
610 G . . G
611 P . . P
612 L . . L
613 V . . V
614 V . . V
615 L . . L
616 L . . L
617 L . . L
618 L . . L
619 L . . L
620 T . . T
621 V . . V
622 G . . G
623 P . . P
624 C . . C
625 L . . L
626 I . . I
627 N . . N
628 R . . R
629 F . . F
630 V . . V
631 A . . A
632 F . . F
633 V . . V
634 R . . R
635 E . . E
636 R . . R
637 V . . V





Amino Acid Position PERV-A(42)-env Wild Type 1st Section 2nd Section 3 rd Section
639 A . . A
640 V . . V
641 Q . . Q
642 I . . I
643 M . . M
644 V . . V
645 L . . L
646 R . . R
647 Q . . Q
648 Q . . Q
649 Y . . Y
650 Q . . Q
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